Jill O'Donnell-Tormey, CEO and Director of Scientific Affairs, chats with STAT about the lifesaving potential of bispecific antibodies.
A new type of antibody that can attach to more than one protein target may change the way cancer is treated.
Take a look at some of the entrants in a hot new field.
- Irene Ghobrial, M.D., Lavine Family Chair of Preventative Cancer Therapy, Professor of Medicine, Dana Farber Cancer Institute
- Jill O’Donnell-Tormey, Ph.D., CEO and Director of Scientific Affairs, Cancer Research Institute
- Damian Garde, National Biotech Reporter, STAT (moderator)
- Tony Polverino, Ph.D., Executive Vice President, Early Development and Chief Scientific Officer, Zymeworks (sponsor speaker)